GLP-1 & Metabolic
Vive GLP(T)
Formula
- Size
- 5mg
Specifications
Vive GLP(T) Technical Profile
OVERVIEW
What Is Tirzepatide Peptide?
Tirzepatide is a synthetic 39-amino-acid peptide designed as a dual agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Built on a native GIP backbone sequence, tirzepatide peptide incorporates specific modifications that enable it to activate both incretin receptor pathways simultaneously. This dual mechanism has made tirzepatide research peptide one of the most significant compounds in modern metabolic research.
The tirzepatide peptide features an aminoisobutyric acid (Aib) substitution at position 2 for DPP-4 resistance and a C-20 fatty diacid moiety linked to lysine-20, facilitating albumin binding and an extended half-life in research models. As a tirzepatide research chemical, it represents a novel approach to studying incretin biology by engaging both the GIP and GLP-1 receptor systems, a strategy that has generated considerable interest in the peptide research community.
- 01
Dual GIP/GLP-1 Receptor Agonist
Synthetic 39-amino acid peptide targeting both incretin receptors
- 02
≥99% HPLC Purity
Every batch verified via high-performance liquid chromatography
- 03
USA Tested & Verified
Third-party analytical testing performed in USA laboratories
RESEARCH
Tirzepatide Mechanism of Action in Research
The tirzepatide mechanism of action involves simultaneous activation of two distinct incretin receptor pathways, a feature that distinguishes it from single-agonist compounds like semaglutide. Tirzepatide research has revealed complex receptor pharmacology that continues to be investigated in preclinical models.
GIP Receptor Agonism
Tirzepatide was designed on a native GIP backbone and demonstrates potent GIP receptor agonism. In research models, GIP receptor activation by tirzepatide has been observed to influence lipid metabolism, adipose tissue function, and bone metabolism pathways. Studies suggest that tirzepatide's GIP receptor activity may be a key differentiating factor in its research profile. Published data indicate that tirzepatide demonstrates approximately equal potency at the GIP receptor compared to native GIP (Coskun et al., Molecular Metabolism, 2018).
GLP-1 Receptor Agonism
In addition to GIP receptor activity, tirzepatide research peptide activates the GLP-1 receptor, engaging the same cAMP-mediated signaling cascades studied with selective GLP-1 agonists. The tirzepatide GIP GLP-1 dual activation is thought to produce complementary and potentially synergistic effects in research settings. Studies indicate tirzepatide's GLP-1 receptor potency is approximately 5-fold lower than native GLP-1, suggesting a biased agonism profile.
Biased Agonism and Receptor Pharmacology
Emerging tirzepatide research has explored the concept of biased agonism at both receptor targets. Studies suggest tirzepatide may preferentially activate certain intracellular signaling pathways over others at each receptor, potentially explaining its distinct pharmacological profile. This area of investigation represents a frontier in incretin receptor biology research. ---
COMPARISON
Tirzepatide vs Retatrutide: Research Peptide Comparison
Tirzepatide
Tirzepatide and retatrutide represent the evolution of multi-receptor agonist peptide research. While tirzepatide is a dual GIP/GLP-1 agonist, retatrutide adds a third target, the glucagon receptor, creating a triple agonist profile.
Retatrutide
Both tirzepatide research peptide and retatrutide are available from VivePeptides at ≥99% purity. Researchers investigating dual incretin signaling typically choose tirzepatide, while those studying the added dimension of glucagon receptor co-agonism may opt for retatrutide.
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor Targets | GIP + GLP-1 (dual agonist) | GIP + GLP-1 + Glucagon (triple agonist) |
| CAS Number | 2023788-19-2 | 2381089-83-2 |
| Molecular Weight | 4813.45 Da | ~4803.75 Da |
| Amino Acids | 39 | 39 |
| Backbone | GIP-based | GIP-based |
| Receptor Count | 2 | 3 |
| Research Stage | Extensively published | Emerging research compound |
| Key Differentiator | Established dual agonist research profile | Addition of glucagon receptor activity |
RESEARCH STUDIES
Tirzepatide Research Applications & Published Studies
Tirzepatide research grade compound has been the subject of rapidly growing preclinical and research literature, with studies published in leading scientific journals examining its dual receptor pharmacology.
Incretin Receptor Pharmacology
Foundational tirzepatide research by Coskun et al. (Molecular Metabolism, 2018) characterized its dual receptor agonism, establishing that tirzepatide demonstrates imbalanced agonism at the GIP and GLP-1 receptors. This research demonstrated that tirzepatide's GIP-to-GLP-1 potency ratio differs from the 1:1 balance, suggesting a unique pharmacological profile that warrants specific investigation.
Metabolic Pathway Studies
Tirzepatide research has included extensive investigation of metabolic pathways in animal models. Studies have documented effects on glucose-stimulated insulin secretion, hepatic lipid metabolism, and energy expenditure parameters in rodent models. Published research indicates that dual GIP/GLP-1 receptor activation may engage metabolic pathways not accessible through single-receptor agonism alone.
Adipose Tissue Biology
A growing area of tirzepatide research focuses on adipose tissue biology. Published studies have examined how dual incretin receptor activation influences adipocyte differentiation, lipid storage, and adipokine expression patterns. These investigations leverage tirzepatide's unique GIP receptor activity, as GIP receptors are expressed in adipose tissue.
QUALITY ASSURANCE
Quality & Testing Standards
VivePeptides ensures every batch of tirzepatide research peptide meets the highest analytical standards.
HPLC & Mass Spectrometry
Every tirzepatide batch undergoes HPLC and mass spectrometry analysis to confirm peptide identity, purity, and correct molecular weight.
Third-Party Verified
All tirzepatide is independently tested at third-party USA-based analytical laboratories with full documentation.
≥99% Purity Standard
VivePeptides tirzepatide consistently meets or exceeds ≥99% purity as verified by HPLC for reliable research outcomes.
FAQ
Frequently Asked Questions About Tirzepatide
What is tirzepatide used for in research?
What purity is VivePeptides tirzepatide?
How should tirzepatide be stored?
What makes tirzepatide different from semaglutide in research?
Is VivePeptides tirzepatide third-party tested?
Add To Research Cart
Vive GLP(T)
99%+ purity · USA lab tested · secure shipping
